Isentress licence extension

Isentress (raltegravir) can now be prescribed for treatment-naïve HIV patients. The integrase inhibitor, which must be given in combination with other antiretrovirals, is approved for use in people aged 16 years or over.

View Isentress drug record

Further information: MSD

To sign up for the MIMS monthly news update, register at

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more